Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia

MLL重排白血病癌基因沉默的表观遗传机制

• 批准号: 9532338
• 负责人: Chun-Wei David Chen
• 金额: $ 24.9万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9532338
• 关键词: Ablation; Achievement; Acute Myelocytic Leukemia; Acute leukemia; Advanced Malignant Neoplasm; Award; Biochemical; Bioinformatics; CRISPR library; Cancer Biology; Chimeric Proteins; Chromatin; Clinical; Clinical Trials; Clustered Regularly Interspaced Short Palindromic Repeats; Data; Deacetylase; Deacetylation; Defect; Development; Development Plans; Disease; Ectopic Expression; Environment; Enzymes; Epigenetic Process; Experimental Hematology; Faculty; Gene Cluster; Gene Expression; Gene Expression Regulation; Gene Rearrangement; Gene Targeting; Generations; Genes; Genetic; Genetic Models; Genetic Transcription; Genomics; Goals; Hematopoiesis; Hematopoietic; Hematopoietic System; Hematopoietic stem cells; High-Throughput Nucleotide Sequencing; Histone Deacetylase; Histone H3; Histones; Human; Individual; K-Series Research Career Programs; Knockout Mice; Knowledge; Laboratories; Laboratory Research; Link; Lysine; MEIS1 gene; MLL gene; MLLT3 gene; Maintenance; Malignant - descriptor; Malignant Neoplasms; Mediating; Medicine; Memorial Sloan-Kettering Cancer Center; Mentors; Mentorship; Mixed-Lineage Leukemia; Mus; Nature; Oncogenes; Oncogenic; Outcome; Pathway interactions; Patients; Pharmacology; Phase; Pilot Projects; Play; Positioning Attribute; Publishing; RNA interference screen; Recruitment Activity; Repression; Research; Research Design; Resistance; Role; SIRT1 gene; Scientist; System; Testing; Training; Treatment Efficacy; Treatment Protocols; Uncertainty; United States National Institutes of Health; Work; Xenograft procedure; base; cancer genetics; cancer therapy; cancer type; career; career development; clinically relevant; conventional therapy; effective therapy; epigenetic profiling; epigenetic regulation; experience; experimental study; gene translocation; genome-wide; histone methyltransferase; histone modification; in vivo Model; inhibitor/antagonist; leukemia; mouse model; novel; novel therapeutics; pediatric patients; pre-clinical; programs; public health relevance; response; small hairpin RNA; tenure track; therapy outcome; tool

 DESCRIPTION (provided by applicant): Although epigenetic dysregulation is already recognized to play an important role in the initiation and progression of many types of cancers, studies on epigenetic cancer therapy have been primarily focused on targeting a single epigenetic regulator to disrupt the maintenance of the disease. The cross-talks between epigenetic pathways that dictate gene expression/silencing and therapeutic outcome are just beginning to gain recognition. This application has immediate clinical relevance since DOT1L inhibitors are now in clinical trials for individuals with MLL-r leukemia. Important clinical responses have been noted with DOT1L inhibitor treatment alone, but there is no doubt that combination approaches will be necessary. The objective in this application is to determine the critical epigenetic effectors and mechanisms that establish oncogene silencing in MLL-r leukemia upon DOT1L inhibition. Preliminary studies based on a genome-scale RNAi screen have identified an essential role of histone deacetylase Sirtuin 1 (SIRT1) in silencing DOT1L-dependent oncogenes in MLL-AF9 leukemia (published in Nature Medicine). This proposed study will further utilize genome-wide genetic and epigenetic research tools to dissect the epigenetic mechanisms underlying the expression and silencing of oncogenes in both MLL-r leukemia and normal hematopoiesis. The proposed application is INNOVATIVE, in our opinion, because it introduces a novel concept of combinational targeting that simultaneously "induces" and "stabilizes" epigenetic silencing for profound oncogene suppression. In addition, this research will be of SIGNIFICANCE because it immediately provides novel therapeutic opportunities against the difficult-to-treat MLL-r leukemias by simultaneously activating the oncogene silencing mechanisms. The Specific Aims of this proposal are: 1. Examine the direct effect of SIRT1 enzymatic activity on silencing DOT1L-driven oncogenes in MLL-r leukemia. 2. Evaluate the efficacy of SIRT1 and DOT1L combinational targeting as a novel therapeutic strategy against MLL-r leukemia. 3. Investigate the role of SIRT1 in silencing DOT1L-dependent genes in hematopoietic stem/progenitor cells. Dr. Chun-Wei David Chen is currently a Senior Research Scientist in the Department of Cancer Biology and Genetics at Memorial Sloan Kettering Cancer Center. Building on his scientific training in epigenetic regulation and experimental hematology, Dr. Chen uncovered and is now investigating the role of SIRT1 and DOT1L interactions in MLL-AF9 leukemia and normal hematopoiesis. His initial achievement identifies cross-inhibitory mechanisms between epigenetic pathways for cancer therapy was recently published in Nature Medicine. His long term goal is to provide novel opportunities for advanced cancer therapies by understanding how epigenetic regulators control gene expression under normal and malignant conditions. Dr. Chen will carry out his proposed project in a stimulating academic environment under the mentorship of Dr. Scott Armstrong, a recognized leader in the fields of leukemia genetics and epigenetics. Dr. Scott A. Armstrong has successfully helped two trainees who have obtained support through the NIH-K99 Career Development Award to obtain tenure-track faculty positions. He has proposed a career development plan to further Dr. Chen's scientific development and to help his transition to independence.

 描述（由申请人提供）：尽管已经认识到表观遗传失调在许多类型癌症的发生和进展中起重要作用，但表观遗传癌症治疗的研究主要集中在靶向单一表观遗传调节因子以破坏疾病的维持。决定基因表达/沉默和治疗结果的表观遗传途径之间的交叉对话刚刚开始获得认可。该应用具有直接的临床相关性，因为DOT 1 L抑制剂目前正在对MLL-r白血病患者进行临床试验。已经注意到单独使用DOT 1 L抑制剂治疗的重要临床反应，但毫无疑问，联合方法将是必要的。本申请的目的是确定DOT 1 L抑制后在MLL-r白血病中建立癌基因沉默的关键表观遗传效应子和机制。基于基因组规模RNAi筛选的初步研究已经确定了组蛋白脱乙酰酶Sirtuin 1（SIRT 1）在MLL-AF 9白血病中沉默DOT 1 L依赖性癌基因中的重要作用（发表在Nature Medicine上）。这项拟议的研究将进一步利用全基因组遗传学和表观遗传学研究工具来剖析MLL-r白血病和正常造血中癌基因表达和沉默的表观遗传学机制。在我们看来，拟议的应用是创新的，因为它引入了一种新的组合靶向概念，同时“诱导”和“稳定”表观遗传沉默，以实现深刻的癌基因抑制。此外，这项研究将具有重要意义，因为它通过同时激活癌基因沉默机制，立即为难治性MLL-r白血病提供了新的治疗机会。本提案的具体目标是：1。检查SIRT 1酶活性对MLL-r白血病中DOT 1 L驱动的癌基因沉默的直接影响。2.评估SIRT 1和DOT 1 L联合靶向作为MLL-r白血病新治疗策略的疗效。3.研究SIRT 1在造血干/祖细胞中沉默DOT 1 L依赖性基因的作用。陈春伟大卫博士目前是纪念斯隆凯特琳癌症中心癌症生物学和遗传学系的高级研究科学家。基于他在表观遗传调控和实验血液学方面的科学训练，Chen博士发现并正在研究SIRT 1和DOT 1 L相互作用在MLL-AF 9白血病和正常造血中的作用。他的初步成果确定了癌症治疗的表观遗传途径之间的交叉抑制机制，最近发表在Nature Medicine上。他的长期目标是通过了解表观遗传调节因子如何在正常和恶性条件下控制基因表达，为先进的癌症治疗提供新的机会。陈博士将在白血病遗传学和表观遗传学领域公认的领导者Scott Armstrong博士的指导下，在一个激励人心的学术环境中开展他的拟议项目。Scott A.阿姆斯特朗已经成功地帮助两名学员谁获得了通过NIH-K99职业发展奖的支持，以获得终身教职。他提出了一个职业发展计划，以促进陈博士的科学发展，并帮助他过渡到独立。